About
Radiopharmaceuticals
Areas of Focus
Categories
DiagnosticsRadiopharmaceuticalsMidwest
Team (2)
Clinical Trials (21)
View allTotal Trials
21
As Lead Sponsor
19
As Collaborator
2
Total Enrollment
1,506
By Phase
PHASE3: 7PHASE2: 6PHASE1: 5PHASE1/PHASE2: 1
By Status
COMPLETED: 10TERMINATED: 7WITHDRAWN: 2UNKNOWN: 2
Clinical Trials Pipeline21 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05246280Lead Sponsor
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
PHASE3Terminated
169 participants
Started: Mar 2, 2022 · Completed: Jul 9, 2024
NCT04078191Lead Sponsor
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
PHASE2Terminated
20 participants
Started: Sep 14, 2021 · Completed: Jul 9, 2024
NCT04947137Lead Sponsor
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
PHASE2Completed
134 participants
Started: May 27, 2021 · Completed: Jan 21, 2022
NCT03938636Lead Sponsor
Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging
PHASE2Completed
116 participants
Started: Apr 8, 2019 · Completed: Jun 30, 2021
NCT03332940Lead Sponsor
Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
PHASE1Terminated
6 participants
Started: Dec 6, 2017 · Completed: Mar 10, 2019
Locations (1)
Headquarters
Columbus, OH, United States
Map
Loading map...